# A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

> **NCT05685173** · PHASE1 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 107 (estimated)

## Conditions studied

- B-cell Non-Hodgkins Lymphoma (B-NHL)

## Interventions

- **DRUG:** Odronextamab
- **DRUG:** REGN5837

## Key facts

- **NCT ID:** NCT05685173
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-20
- **Primary completion:** 2029-02-16
- **Final completion:** 2030-01-13
- **Target enrollment:** 107 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05685173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05685173, "A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05685173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*